Agios Pharmaceuticals Inc
NASDAQ:AGIO

Watchlist Manager
Agios Pharmaceuticals Inc Logo
Agios Pharmaceuticals Inc
NASDAQ:AGIO
Watchlist
Price: 30.17 USD 1.11% Market Closed
Market Cap: 1.7B USD

Operating Margin
Agios Pharmaceuticals Inc

1 752%
Current
-5 373%
Average
-6%
Industry

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1 752%
=
Operating Profit
648.8m
/
Revenue
37m

Operating Margin Across Competitors

Agios Pharmaceuticals Inc
Glance View

Market Cap
1.7B USD
Industry
Biotechnology

Amid the thriving hub of biotechnology in Cambridge, Massachusetts, Agios Pharmaceuticals Inc. carved a niche for itself with a focused approach on rare and genetically defined diseases. From its inception, Agios set out to revolutionize the treatment landscape by diving into cellular metabolism's intricacies. This was a path less traveled, yet it held the potential to unlock therapies where few solutions previously existed. The company's initial explorations into cancer metabolism pioneered innovative treatments for various malignancies. However, the agility of Agios’s strategic vision was evident when it pivoted to concentrate its resources on the profound potential of precision medicines tailored for unheard-of-conditions like pyruvate kinase deficiency (PKD). To understand how Agios generates revenue, consider its commitment to harnessing deep scientific insights and translating them into impactful therapies. Agios’s revenue model involves the development and commercialization of pioneering therapies that address unmet medical needs, often collaborating with strategic partners to amplify its reach and efficacy in bringing these treatments to market. Moving beyond oncology, the firm now monetizes its research by focusing on a single area of expertise, shifting from developing cancer drugs to innovating within rare genetic disorders. This focused strategy is epitomized by their lead product for PKD, a chronic hemolytic anemia, leading to a revenue model intricately linked to their ability to develop and deliver highly specialized treatments that make a real-world impact on patient lives.

AGIO Intrinsic Value
28.32 USD
Overvaluation 6%
Intrinsic Value
Price
What is Operating Margin?

Operating Margin represents how efficiently a company is able to generate profit through its core operations.

Higher ratios are generally better, illustrating the company is efficient in its operations and is good at turning sales into profits.

Operating Margin
1 752%
=
Operating Profit
648.8m
/
Revenue
37m
What is the Operating Margin of Agios Pharmaceuticals Inc?

Based on Agios Pharmaceuticals Inc's most recent financial statements, the company has Operating Margin of 1 752%.

Back to Top